Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer

International Journal of Radiation Oncology Biology Physics

Volumn 35, Issue 3, 1996, Pages 425-438

  Fu, Karen K ^a,j   Cooper, Jay S ^b   Marcial, Victor A ^c   Laramore, George E ^d   Pajak, Thomas F ^e   Jacobs, John ^f   Al Sarraf, Muhyi ^g   Forastiere, Arlene A ^h   Cox, James D ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Department of Statistics   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g Providence Hypnosis Center   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Clinical trials; Combined modality; Head and neck cancer; Radiotherapy; RTOG

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOGEN; CISPLATIN; CYCLOPHOSPHAMIDE; ETANIDAZOLE; FLUOROURACIL; ISOTRETINOIN; METHOTREXATE; MISONIDAZOLE; TUMOR ANTIGEN; VINCRISTINE;

ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; HEAD AND NECK CANCER; HUMAN; HYPOXIC CELL; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; ORGAN PRESERVATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION;

EID: 0030175537     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)80003-4     Document Type: Article

References (67)

1. 1. Al-Sarraf, M.; LeBlanc, M.; Giri, P. S.; Fu, K. K.; Cooper, J. S.; Souhami, L.; Forastiere, A.; Sakar, W.; Schuller, D.; Ensley, J. Superiority of chemo-radiotherapy (CT-RT) compared to radiotherapy alone for patients with locally advanced nasopharyngeal cancer: preliminary results of Intergroup 0099 (SWOG 8892, RTOG 8817, ECOG 2388) randomized study. Proc. Am. Soc. Clin. Oncol. 15:313; 1996.
2. 2. Al-Sarraf, M.; Pajak, T.; Byhardt, R.; Beitler, J. I.; Salter, M. M.; Cooper, J. S. Postoperative radiotherapy with concurrent cisplatin appears to improve local-regional control of advanced, resectable head and neck cancers. RTOG 88-24. Int. J. Radiat. Oncol. Biol. Phys. (submitted) .
3. 3. Al-Sarraf, M.; Pajak, T. F.; Cooper, J. S.; Mohiuddin, M.; Herskovic, A.; Ager, P. J. Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a Radiation Therapy Oncology Group study. J. Clin. Oncol. 8:1342-1351; 1990.
4. 4. Ang, K. K.; Peters, L. J. Altered fractionation in radiation oncology. DeVita, V. T.; Hellman, S.; Rosenberg, S. A., eds. In: Principles and practices of oncology. PPO updates, Vol. 8. Philadelphia: J. B. Lippincott Co.; 1994.
5. 5. Ang, K. K.; Peters, L. J.; Weber, R. S.; Maor, M. H.; Morrison, W. H.; Wendt, C. D.; Brown, B. W. Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int. J. Radiat. Oncol. Biol. Phys. 19:1339-1345; 1990.
6. 6. Bachaud, J. M.; David, J. M.; Boussin, G.; Daly, N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: preliminary report of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 20:243-246; 1991.
7. 7. Bataini, J. P.; Ennuyer, A.; Poncet, P.; Ghossein, N. A. Treatment of supraglottic cancer by radical high dose radiotherapy. Cancer 33:1253-1262; 1974.
8. 8. Beahrs, O. H.; Henson, D. E.; Hutter, R. V. P.; Kennedy, B. J., eds. Manual for staging of cancer. 4th ed. Philadelphia, PA: Lippincott Co.; 1992.
9. 9. Begg, A. C.; Hofland, I.; Van Glabekke, M.; Bartelink, H.; Horiot, J. C. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: Results from the EORTC cooperative trial 22851. Sem. Radiat. Oncol. 2:21-25; 1992.
10. 10. Bigler, S. A.; Deering, R. E.; Brawer, M. K. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum. Pathol. 24:220-226; 1993.
11. 11. Cooper, J. S.; Farnan, N. C.; Asbell, S. O.; Rotman, M.; Marcial, V.; Fu, K. K.; McKenna, W. G.; Emami, B. Recursive partitioning analysis of 2,105 patients treated in RTOG studies of head and neck cancer. Cancer 77:1905-1911; 1996.
12. 12. Cooper, J. S.; Pajak, T. F.; Rubin, P.; Tupchong, L.; Brady, L. W.; Leibel, S. A.; Laramore, G. E.; Marcial, V. A.; Davis, L. W.; Cox, J. D.; et. al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int. J. Radiat. Oncol. Biol. Phys. 17:449-456; 1989.
13. 13. Cooper, J. S.; Scott, C.; Marcial, V.; Griffin, T.; Fazekas, J.; Laramore, G.; Hoffman, A. The relationship of nasopharyngeal carcinomas and second independent malignancies based on the Radiation Therapy Oncology Group experience. Cancer 67:1673-1677; 1991.
14. 14. Cox, J. D.; Pajak, T. F.; Marcial, V. A.; Coia, L.; Mohiuddin, M.; Fu, K. K.; Selim, H.; Byhardt, R.; Rubin, P.; Ortiz, H.; Martin, L. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. Cancer 69:2744-2748; 1992.
15. 15. Cox, J. D.; Pajak, T. F.; Marcial, V. A.; Coia, L.; Mohiuddin, M.; Fu, K. K.; Selim, H.; Rubin, P.; Ortiz, H. ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313. Int. J. Radiat. Oncol. Biol. Phys. 20:1191-1195; 1991.
16. 16. Cox, J. D.; Pajak, T. F.; Marcial, V. A.; Hanks, G. E.; Mohiuddin, M.; Fu, K. K.; Byhardt, R. W.; Rubin, P. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of Radiation Therapy Oncology Group protocol 83-13. Int. J. Radiat. Oncol. Biol. Phys. 18:515-521; 1990.
17. 17. Fazekas, J. T.; Goodman, R. L.; McLean, C. J. The value of adjuvant misonidazole in the definitive irradiation of advanced head and neck squamous cancer: an RTOG pilot study (#78-02). Int. J. Radiat. Oncol. Biol. Phys. 7:1703-1708; 1981.
18. 18. Fazekas, J.; Pajak, T. F.; Wasserman, T.; Marcial, V.; Davis, L.; Kramer, S.; Rotman, M.; Stetz, J. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 13:1155-1160; 1987.
19. 19. Fazekas, J. T.; Sommer, C.; Kramer, S. Adjuvant intravenous methotrexate or definitive radiotherapy alone for advanced squamous cancers of the oral cavity, oropharynx, supraglottic larynx or hypopharynx. Int. J. Radiat. Oncol. Biol. Phys. 6:533-541; 1980.
20. 20. Figueroa, V. N.; Marcial, V. A.; Vélez, G. E.; Cintrón, J.; Vallecillo, L. A. Multidrug chemotherapy (vincristine-bleomycin-methotrexate) followed by radiotherapy in inoperable carcinomas of the head and neck: a pilot study of the Radiation Therapy Oncology Group. Am. J. Clin. Oncol. 5:399-404; 1982.
21. 21. Folkman, J. What is the evidence that tumors are angiogenesis dependent? [editorial]. J. Natl. Cancer Inst. 82:4-6; 1990.
22. 22. Fu, K. K.; Hammond, E.; Pajak, T. F.; Clery, M.; Doggett, R. L. S.; Byhardt, R. W.; McDonald, S.; Cooper, J. S. Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head & neck cancers: results of RTOG 91-08. Int. J. Radiat. Oncol. Biol. Phys. 29:661-671; 1994.
23. 23. Fu, K. K.; Pajak, T. F.; Ang, K. K.; Byhardt, R. W.; Maor, M. H.; Beitler, J. J. Randomized Phase I/II trial of two variants of accelerated fractionation radiotherapy regimens for advanced head and neck cancer: Results of RTOG 88-09. Int. J. Radiat. Oncol. Biol. Phys. 32:589-598; 1995.
24. 24. Fu, K.; Pajak, T.; Marcial, V.; Ortiz, H.; Rotman, M.; Asbell, S.; Coia, L.; Vora, N.; Byhardt, R.; Rubin, P.; Sorgen, S.; Cox, J. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: Long-term follow-up results of RTOG 83-13. Int. J. Radiat. Oncol. Biol. Phys. 32:577-588; 1995.
25. 25. Fu, K. K.; Silverberg, I. J.; Phillips, T. L.; Friedman, M. A. Combined radiotherapy and multidrug chemotherapy for advanced head and neck cancer: Results of a Radiation Therapy Oncology Group pilot study. Cancer Treat. Rep. 63:351-357; 1979.
26. 26. Gasparini, G.; Weidner, N.; Maluta, S.; Pozza, F.; Boracchi, P.; Mezzetti, M.; Testolin, A.; Bevilacqua, P. Intratumoral microvessel density and p53 protein: Correlation with metastasis in head and neck squamous cell carcinoma. Int. J. Cancer 55:739-744; 1993.
27. 27. Glick, J. H.; Marcial, V.; Richter, M.; Velez, G. E. The adjuvant treatment of inoperable stage III and IV epidermoid carcinoma of the head and neck with platinum and bleomycin infusions prior to definitive radiotherapy: an RTOG pilot study. Cancer 46:1919-1924; 1980.
28. 28. Griffin, T. W.; Pajak, T. F.; Gillespie, B. W.; Davis, L. W.; Brady, L. W.; Rubin, P.; Marcial, V. A. Predicting the response of head and neck cancers to radiation therapy with a multivariate modeling system: an analysis of the RTOG head and neck registry. Int. J. Radiat. Oncol. Biol. Phys. 10:481-487; 1984.
29. 29. Hanson, W. R.; Marks, J. E.; Reddy, S. P.; Simon, S.; Mihalo, W. E.; Toval, Y. Protection from radiation-induced oral mucositis by misoprostol, a prostaglandin E1 analog: a placebo-controlled, double-blind clinical trial. Am. J. Ther. 2:1-8; 1995.
30. 30. Harwood, A. R.; Beale, F. A.; Cummings, B. J.; Keane, T. J.; Payne, D.; Rider, W. D. T4NOMO glottic cancer: an analysis of dose-time volume factors. Int. J. Radiat. Oncol. Biol. Phys. 7:1507-1512; 1981.
31. 31. Harwood, A. R.; Bryce, D. P.; Rider, W. D. Management of T3 glottic cancer. Arch. Otolaryngol. 106:697-699; 1980.
32. 32. Haselow, R. E.; Warshaw, M. G.; Oken, M. M.; Adams, G. L.; Aughey, J. L.; Cooper, J. S.; Schuller, D. E.; Jacobs, C. D. Radiation alone vs. radiation with weekly low dose cisplatinum in unresectable cancer of the head and neck. In: Fee, W. E.; Goepfert, H.; Johns, M. E.; Strong, E. W.; Ward, P. H., eds. Head and Neck Cancer. Vol. II. Toronto: B. C. Decker, Inc.; 1990:279-281.
33. 33. Hong, W. K.; Lippman, S. M.; Itri, L. M.; Karp, D. D.; Lee, J. S.; Byers, R. M.; Schantz, S. P.; Kramer, A. M.; Lotan, L. J.; Peters, L. J.; et. al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N. Engl. J. Med. 323:795-801; 1990.
34. 34. Horiot, J. C.; Le, F. R.; N'Guyen, T.; Chenal, C.; Schraub, S.; Alfonsi, S.; Gardani, G.; van den Bogaert, W; Danczak, S.; Bolla, M.; et. al. Hyperfractionation vs. conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy [see comments]. Radiother. Oncol. 25:231-241; 1992.
35. 35. Jacobs, J. R.; Fu, K. K.; Lowry, L. D.; Dogett, R. L. S.; Pajak, T. F.; Al-Sarraf, M. 5-year results of cisplatin and fluorouracil infusion in head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 117:288-291; 1991.
36. 36. Kramer, S.; Gelber, R. D.; Snow, J. B.; Marcial, V. A.; Lowry, L. D.; Davis, L. W.; Chandler, R. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg. 10:19-30; 1987.
37. 37. Laramore, G. E.; Scott, C. B.; Al-Sarraf, M.; Haselow, R. E.; Ervin, T. J.; Wheeler, R.; Jacobs, J. R.; Schuller, D. E.; Gahbauer, R. A.; Schwade, J. G.; et. al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034 [see comments]. Int. J. Radiat. Oncol. Biol. Phys. 23:705-713; 1992.
38. 38. Lee, D. J.; Cosmatos, D.; Marcial, V. A.; Fu, K. K.; Rotman, M.; Cooper, J. S.; Ortiz, H. G.; Beitler, J. J.; Abrams, R. A.; Curran, W. J.; Coleman, N.; Wasserman, T. H. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 32:567-576; 1995.
39. 39. Lee, D. J.; Pajak, T. F.; Stetz, J.; Order, S. E.; Weissberg, J. B.; Fischer, J. J. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractionated dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). Int. J. Radiat. Oncol. Biol. Phys. 16:465-470; 1989.
40. 40. Leibel, S. A.; Scott, C. B.; Mohiuddin, M.; Marcial, V. A.; Coia, L. R.; Davis, L. W.; Fuks, Z. The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database. Int. J. Radiat. Oncol. Biol. Phys. 21:549-556; 1991.
41. 41. Lippman, S. M.; Batsakis, J. G.; Toth, B. B.; Weber, R. S.: Lee, J. J.; Martin, J. W.; Hays, G. L.; Goepfert, H.; Hong, W. K. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N. Engl. J. Med. 328:15-20; 1993.
42. 42. Lippman, S. M.; Spitz, M. R.; Huber, M. H.; Hong, W. K. Strategies for chemoprevention study of premalignancy and second primary tumors in the head and neck. Curr. Opin. Oncol. 7:234-241; 1995.
43. 43. Macchiarini, P.; Fontaini, G.; Hardin, M. J. Relation of neovasculature to metastasis of non-small cell lung cancer. Lancet 340:145-146; 1992.
44. 44. Marcial, V. A.; Amato, D. A.; Marks, R. D.; Rotman, M.; Canoy, N.; Figueroa, V. N.; Hanley, J. A. Split-course vs. continuous pelvis irradiation in carcinoma of the uterine cervix: a prospective randomized clinical trial of the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 9:431-436; 1983.
45. 45. Marcial, V. A.; Hanley, J. A.; Chang, C.; Davis, L. W.; Moscol, J. A. Split-course radiation therapy of carcinoma of the nasopharynx: Results of a national collaborative clinical trial of the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 6:409-414; 1980.
46. 46. Marcial, V. A.; Pajak, T. F.; Chang, C.; Tupchong, L.; Stetz, J. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (Preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int. J. Radiat. Oncol. Biol. Phys. 13:41-47; 1987.
47. 47. Marcial, V. A.; Pajak, T. F.; Kramer, S.; Davis, L. W.; Stetz, J.; Laramore, G. E.; Jacobs, J. R.; Al-Sarraf, M.; Brady, L. W. Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer. Semin. Oncol. 15:39-60; 1988.
48. 48. Marcial, V. A.; Pajak, T. F.; Mohiuddin, M.; Cooper, J. S.; Al-Sarraf, M.; Mowry, P. A.; Curran, W.; Crissman, J.; Rodríguez, M.; Vílez, G. E. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck: Long-term results of the Radiation Therapy Oncology Group study 81-17. Cancer 66:1861-1868; 1990.
49. 49. Marcial, V. A.; Pajak, T. F.; Rotman, M.; Brady, L. W.; Amato, D. "Compensated" split-course vs. continuous radiation therapy of carcinoma of the tonsillar fossa: Final results of a prospective randomized clinical trial of the Radiation Therapy Oncology Group. Am. J. Clin. Oncol. 16:389-396; 1993.
50. 50. Parsons, J. T.; Mendenhall, W. M.; Stringer, S. P.; Cassisi, N. J.; Million, R. R. Twice-a-day radiotherapy for squamous cell carcinoma of the head and neck: The University of Florida experience. Head Neck 15:87-96; 1993.
51. 51. Peters, L. J. Accelerated fractionation using the concomitant boost: a contribution of radiobiology to radiotherapy. Bjr. Suppl. 24:200-203; 1992.
52. 2 expression. Cancer 77:1419-1426; 1996.
53. 53. Rubin, P.; Hanley, J.; Keys, H. M.; Marcial, V.; Brady, L. Carbogen breathing during radiation therapy - the Radiation Therapy Oncology Group Study. Int. J. Radiat. Oncol. Biol. Phys. 5:1963-1970; 1979.
54. 54. Saunders, M. I.; Dische, S.; Grosch, E. J.; Ferment, D. C.; Ashford, R. F.; Maher, E. J.; Makepeace, A. R. Experience with CHART. Int. J. Radiat. Oncol. Biol. Phys. 21:871-878; 1991.
55. 55. Schuller, D. E.; Metch, B.; Stein, D. D. M.; McCraken, J. D. Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope 98:1205-1211; 1988.
56. 56. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med. 324:1685-1690; 1991.
57. 57. The Head and Neck Contracts Program. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Cancer 60:301-311; 1987.
58. 58. Tupchong, L.; Scott, C. B.; Blitzer, P. H.; Marcial, V. A.; Lowry, L. D.; Jacobs, J. R.; Stetz, J.; Davis, L. W.; Snow, J. B.; Chandler, R.; et. al. Randomized study of preoperative vs. postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int. J. Radiat. Oncol. Biol. Phys. 20:21-28; 1991.
59. 59. van den Bogaert, W.; Ostyn, F.; van der Schueren, E. The primary treatment of advanced vocal cord cancer: laryngectomy or radiotherapy? Int. J. Radiat. Oncol. Biol. Phys. 9:329-334; 1983.
60. 60. Vokes, E.; Harraf, D. J.; Mick, R.; McEvilly, J. M.; Weichselbaum, R. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J. Clin. Oncol. 12:2351-2359; 1994.
61. 61. Wakui, S.; Furusato, M.; Itoh, T.; Sasaki, H.; Akiyama, A.; Kinoshita, I.; Asano, K.; Tokuda, T.; Aizawa, S.; Ushigome, S. Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J. Pathol. 168:257-262; 1992.
62. 62. Wang, C. C. Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes. Int. J. Radiat. Oncol. Biol. Phys. 14:1143-1146; 1988.
63. 63. Wang, C. C.; Blitzer, P. H.; Suit, H. D. Twice-a-day radiation therapy for cancer of the head and neck. Cancer 2100-2104; 1985.
64. 64. Wang, C. C.; Suit, H. D.; Blitzer, P. H. Twice-a-day radiation therapy for supraglottic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 12:3-7; 1986.
65. 65. Weidner, N.; Folkman, J.; Pozza, F.; Bevilacqua, P.; Allred, E. N.; Moore, D. H.; Meli, S.; Gasparini, G. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma [see comments]. J. Natl. Cancer Inst. 84:1875-1887; 1992.
66. 66. Weidner, N.; Semple, J. P.; Welch, W. R.; Folkman, J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 324:1-8; 1991.
67. 67. Williams, J. K.; Carlson, G. W.; Cohen, C.; Derose, P. B.; Hunter, S.; Jurkiewicz, M. J. Tumor angiogenesis as a prognostic factor in oral cavity tumors. Am. J. Surg. 168:373-380; 1994.